Advanced search
Publication Cover
Journal of Experimental Nanoscience Volume 17, 2022 - Issue 1
Submit an article Journal homepage
1,646
Views
1
CrossRef citations to date
0
Altmetric
Articles

Synthesis, crystal structure, hirshfeld surface analysis, molecular docking and molecular dynamics studies of novel olanzapinium 2,5-dihydroxybenzoate as potential and active antipsychotic compound

V. Natchimuthua Department of Physics, M.Kumarasamy College of Engineering, Karur, Tamil Nadu, IndiaORCID Iconhttps://orcid.org/0000-0002-8808-6392
ORCID Icon,
Mohnad Abdallab Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, PR ChinaORCID Iconhttps://orcid.org/0000-0002-1682-5547
ORCID Icon,
Manasi Yadavc In silico Research Laboratory, Eminent Biosciences, Indore, Madhya Pradesh, IndiaORCID Iconhttps://orcid.org/0000-0003-2999-3467
ORCID Icon,
Ishita Choprac In silico Research Laboratory, Eminent Biosciences, Indore, Madhya Pradesh, IndiaORCID Iconhttps://orcid.org/0000-0002-6215-6380
ORCID Icon,
Anushka Bhrdwajc In silico Research Laboratory, Eminent Biosciences, Indore, Madhya Pradesh, India;d Bioinformatics Research Laboratory, LeGene Biosciences Pvt Ltd, Indore, Madhya Pradesh, IndiaORCID Iconhttps://orcid.org/0000-0002-8219-3285
ORCID Icon,
Khushboo Sharmac In silico Research Laboratory, Eminent Biosciences, Indore, Madhya Pradesh, IndiaORCID Iconhttps://orcid.org/0000-0002-4381-5539
ORCID Icon,
S. Ravie PG & Research Department of Physics, National College, Affiliated to Bharathidasan University, Tiruchirapalli, Tamil Nadu, IndiaORCID Iconhttps://orcid.org/0000-0002-0399-2039
ORCID Icon,
Krishnan Ravikumarf X-ray Crystallography Division, CSIR-Indian Institute of Chemical Technology(IICT), Hyderabad, IndiaORCID Iconhttps://orcid.org/0000-0002-6752-9086
ORCID Icon,
Khalid J. Alzahranig Department of Clinical Laboratories sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0002-6688-0106
ORCID Icon,
Tajamul Hussainh Research Chair for Biomedical Applications of Nanomaterials, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia;i Center of Excellence in Biotechnology Research, College of Science, King Saud University, Riyadh, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0001-7601-1417
ORCID Icon &
Anuraj Nayarisseric In silico Research Laboratory, Eminent Biosciences, Indore, Madhya Pradesh, India;d Bioinformatics Research Laboratory, LeGene Biosciences Pvt Ltd, Indore, Madhya Pradesh, India;h Research Chair for Biomedical Applications of Nanomaterials, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi ArabiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2567-9630
ORCID Icon show all
Pages 247-273 | Received 14 Feb 2022, Accepted 17 Mar 2022, Published online: 15 Apr 2022

References

  • Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001; 179:290–299.
  • Chakrabarti JK, Hotten TM, Tupper DE. 2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine US Patent No. 5229382 A, 1993.
  • Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.
  • Smith RC, Infante M, Singh A, et al. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol. 2001; 4(3):239–250.
  • Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther. 1992; 262(2):545–551.
  • Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs. 1993; 2:281–293.
  • Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm (Vienna)). 2002; 109(3):411–420.
  • Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005;20(1):15–27.
  • Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261(5562):717–719.
  • Breden EL, Liu MT, Dean SR, et al. Metabolic and cardiacs side effects of second- generation antipsychotics: what every clinician should known. J Res Pharmacy Pract. 2009;22(5):478–488.
  • Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001; 62:41–44.
  • Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703–1711.
  • Mathews M, Muzina JD. Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med. 2007;74(8):597–606.
  • Gümüş M, Babacan ŞN, Demir Y, et al. Discovery of sulfadrug–pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors. Arch Pharm. 2022;355(1):2100242.
  • Bruker SAINT (version 6.28a) & SMART (version 5.625). Madison, Wisconsin: Bruker AXS Inc, 2001.
  • Sharma K, Patidar K, Ali MA, et al. Structure-based virtual screening for the identification of high affinity compounds as potent VEGFR2 inhibitors for the treatment of renal cell carcinoma. Curr Top Med Chem. 2018;18(25):2174–2185.
  • Sahila MM, Babitha PP, Bandaru S, et al. Molecular docking based screening of GABA (A) receptor inhibitors from plant derivatives. Bioinformation. 2015;11(6):280–289.
  • Vuree S, Dunna NR, Khan IA, et al. Pharmacogenomics of drug resistance in breast cancer resistance protein (BCRP) and its mutated variants. J Pharm Res. 2013;6(7):791–798.
  • Monteiro AFM, Viana JDO, Nayarisseri A, et al. Computational studies applied to flavonoids against Alzheimer’s and Parkinson’s diseases. Oxid Med Cell Longev. 2018;2018:7912765.
  • Bandaru S, Sumithnath TG, Sharda S, et al. Helix-coil transition signatures B-Raf V600E mutation and virtual screening for inhibitors directed against mutant B-Raf. Curr Drug Metab. 2017;18(6):527–534.
  • Kelotra A, Gokhale SM, Kelotra S, et al. Alkyloxy carbonyl modified hexapeptides as a high affinity compounds for Wnt5A protein in the treatment of psoriasis. Bioinformation. 2014;10(12):743–749.
  • Basak SC, Nayarisseri A, González-Díaz H, et al. Editorial (thematic issue: chemoinformatics models for pharmaceutical design, part 1). Curr Pharm Des. 2016;22(33):5041–5042.
  • Basak SC, Nayarisseri A, González-Díaz H, et al. Editorial (thematic issue: chemoinformatics models for pharmaceutical design. Curr Pharm Des. 2016;22(34):5177–5178.
  • Prajapati L, Khandelwal R, Yogalakshmi KN, et al. Computer-aided structure prediction of bluetongue virus coat protein VP2 assisted by optimized potential for liquid simulations (OPLS). Curr Top Med Chem. 2020;20(19):1720–1732.
  • Nayarisseri A, Khandelwal R, Madhavi M, et al. Shape-based machine learning models for the potential novel COVID-19 protease inhibitors assisted by molecular dynamics simulation. Curr Top Med Chem. 2020;20(24):2146–2167.
  • Nayarisseri A. Most promising compounds for treating COVID-19 and recent trends in antimicrobial & antifungal agents. Curr Top Med Chem. 2020;20(24):2119–2125.
  • Pochetti G, Mitro N, Lavecchia A, et al. Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis . J Med Chem. 2010;53(11):4354–4366.
  • Soares Rodrigues GC, dos Santos Maia M, Muratov EN, et al. Quantitative structure–activity relationship modeling and docking of monoterpenes with insecticidal activity against reticulitermes chinensis snyder and Drosophila melanogaster. J Agric Food Chem. 2020;68(16):4687–4698.
  • Wang Y, Wang LF, Zhang LL, et al. Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies. SAR QSAR Environ Res. 2020;31(2):149–170.
  • Marunnan SM, Pulikkal BP, Jabamalairaj A, et al. Development of MLR and SVM aided QSAR models to identify common SAR of GABA uptake herbal inhibitors used in the treatment of schizophrenia. Curr Neuropharmacol. 2017;15(8):1085–1092.
  • Sweta J, Khandelwal R, Srinitha S, et al. Identification of high-affinity small molecule targeting IDH2 for the clinical treatment of acute myeloid leukemia. Asian Pac J Cancer Prev. 2019;20(8):2287–2297.
  • Nayarisseri A. Prospects of utilizing computational techniques for the treatment of human diseases. Curr Top Med Chem. 2019;19(13):1071–1074.
  • Schrodinger, LLC, NY, USA, 2009.
  • LigPrep, Schrodinger LLC, New York, NY, 2017.
  • Prime, Schrodinger, LLC, Ney York, NY, 2019.
  • Protein Preparation Wizard, Schrodinger, LLC, Ney York, NY, 2017.
  • Qikprop, Schrodinger, LLC, Ney York, NY, 2011.
  • Wang LF, Wang Y, Yang ZY, et al. Revealing binding selectivity of inhibitors toward bromodomain-containing proteins 2 and 4 using multiple short molecular dynamics simulations and free energy analyses. SAR QSAR Environ Res. 2020;31(5):373–398.
  • Brugnoni M, Scotti A, Rudov AA, et al. Swelling of a responsive network within different constraints in multi-thermosensitive microgels. Macromolecules. 2018;51(7):2662–2671.
  • Montanari R, Saccoccia F, Scotti E, et al. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. J Med Chem. 2008;51(24):7768–7776.
  • Wang J, Qian Y, Li L, et al. Atomic force microscopy and molecular dynamics simulations for study of lignin solution self-assembly mechanisms in organic-aqueous solvent mixtures. ChemSusChem. 2020;13(17):4420–4427.
  • Liguori N, Croce R, Marrink SJ, et al. Molecular dynamics simulations in photosynthesis. Photosynth Res. 2020;144(2):273–295.
  • Kuzmanic A, Bowman GR, Juarez-Jimenez J, et al. Investigating cryptic binding sites by molecular dynamics simulations. Acc Chem Res. 2020;53(3):654–661.
  • Klesse G, Rao S, Tucker SJ, et al. Induced polarization in molecular dynamics simulations of the 5-HT3 receptor channel. J Am Chem Soc. 2020;142(20):9415–9427.
  • Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95(7):927–937.
  • Berman H, Henrick K, Nakamura H, et al. The worldwide protein data bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic Acids Res. 2007;35(Database issue):D301–D303.
  • Natchimuthu V, Bandaru S, Nayarisseri A, et al. Design, synthesis and computational evaluation of a novel intermediate salt of N-cyclohexyl-N-(cyclohexylcarbamoyl)-4-(trifluoromethyl) benzamide as potential potassium channel blocker in epileptic paroxysmal seizures. Comput Biol Chem. 2016;64:64–73.
  • Bandaru S, Alvala M, Akka J, et al. Identification of small molecule as a high affinity β2 agonist promiscuously targeting wild and mutated (Thr164Ile) β 2 adrenergic receptor in the treatment of bronchial asthma. CPD. 2016;22(34):5221–5233.
  • Majhi M, Ali MA, Limaye A, et al. An in silico investigation of potential EGFR inhibitors for the clinical treatment of colorectal cancer. Curr Top Med Chem. 2018;18(27):2355–2366.
  • Khandelwal R, Chauhan AP, Bilawat S, et al. Structure-based virtual screening for the identification of high-affinity small molecule towards STAT3 for the clinical treatment of osteosarcoma. Curr Top Med Chem. 2018;18(29):2511–2526.
  • Sinha K, Majhi M, Thakur G, et al. Computer-aided drug designing for the identification of high-affinity small molecule targeting cd20 for the clinical treatment of chronic lymphocytic leukemia (CLL). Curr Top Med Chem. 2018;18(29):2527–2542.
  • Chandrakar B, Jain A, Roy S, et al. Molecular modeling of Acetyl-CoA carboxylase (ACC) from jatropha curcas and virtual screening for identification of inhibitors. J Pharm Res. 2013;6(9):913–918.
  • Nayarisseri A, Moghni SM, Yadav M, et al. In silico investigations on HSP90 and its inhibition for the therapeutic prevention of breast cancer. J Pharm Res. 2013;7(2):150–156.
  • Udhwani T, Mukherjee S, Sharma K, et al. Design of PD-L1 inhibitors for lung cancer. Bioinformation. 2019;15(2):139–150.
  • Shukla P, Khandelwal R, Sharma D, et al. Virtual screening of IL-6 inhibitors for idiopathic arthritis. Bioinformation. 2019;15(2):121–130.
  • Nayarisseri A, Hood EA. Advancement in microbial cheminformatics. Curr Top Med Chem. 2018;18(29):2459–2461.
  • Jain D, Udhwani T, Sharma S, et al. Design of novel JAK3 inhibitors towards rheumatoid arthritis using molecular docking analysis. Bioinformation. 2019;15(2):68–78.
  • Nayarisseri A, Singh SK. Functional inhibition of VEGF and EGFR suppressors in cancer treatment. CTMC. 2019;19(3):178–179.
  • Gokhale P, Chauhan APS, Arora A, et al. FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia. Bioinformation. 2019;15(2):104–115.
  • Ali MA, Vuree S, Goud H, et al. Identification of high-affinity small molecules targeting gamma secretase for the treatment of alzheimer’s disease. CTMC. 2019;19(13):1173–1187.
  • Patidar K, Panwar U, Vuree S, et al. An in silico approach to identify high affinity small molecule targeting m-TOR inhibitors for the clinical treatment of breast cancer. Asian Pac J Cancer Prev. 2019;20(4):1229–1241.
  • Pandey N, Yadav M, Nayarisseri A, et al. Cross evaluation of different classes of alpha-adrenergic receptor antagonists to identify overlapping pharmacophoric requirements. J Pharm Res. 2013;6(1):173–178.
  • Shelley JC, Cholleti A, Frye LL, et al. Epik: a software program for pK a prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 2007;21(12):681–691.
  • Baby K, Maity S, Mehta CH, et al. Targeting SARS-CoV-2 main protease: a computational drug repurposing study. Arch Med Res. 2021;52(1):38–47.
  • Gahlawat A, Kumar N, Kumar R, et al. Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease. J Chem Inf Model. 2020;60(12):5781–5793.
  • Shivanika C, Deepak Kumar S, Ragunathan V, et al. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. J Biomol Struct Dyn. 2020.
  • Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Biol. 2002;9(9):646–652.
  • Beura S, &Prabhakar C, In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. J Biomol Struct Dyn. 2021;39(10):3747–2597. Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, … Zhang L. 2016; AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Molecular Cancer Therapeutics.
  • Sharda S, Khandelwal R, Adhikary R, et al. A computer-aided drug designing for pharmacological inhibition of mutant ALK for the treatment of non-small cell lung cancer. CTMC. 2019;19(13):1129–1144.
  • Limaye A, Sweta J, Madhavi M, et al. In silico insights on GD2: a potential target for pediatric Neuroblastoma. Curr Top Med Chem. 2019;19(30):2766–2781.
  • Nayarisseri A, Yadav M. Editorial (thematic issue: mechanistics in drug design-experimental molecular biology vs. molecular modeling). CTMC. 2015;15(1):3–4.
  • Kleandrova VV, Scotti MT, Scotti L, et al. Cell-based multi-target QSAR model for design of virtual versatile inhibitors of liver cancer cell lines. SAR QSAR Environ Res. 2020;31(11):815–836.
  • Nayarisseri A. Experimental and computational approaches to improve binding affinity in chemical biology and drug discovery. Curr Top Med Chem. 2020;20(19):1651–1660.
  • Kaushik AC, Kumar S, Wei DQ, et al. Structure based virtual screening studies to identify novel potential compounds for GPR142 and their relative dynamic analysis for study of type 2 diabetes. Front Chem. 2018;6:23.
  • Toledo Warshaviak D, Golan G, Borrelli KW, et al. Structure-based virtual screening approach for discovery of covalently bound ligands. J Chem Inf Model. 2014;54(7):1941–1950.
  • Sert Y, Gümüş M, Gökce H, et al. Molecular docking, hirshfeld surface, structural, spectroscopic, electronic, NLO and thermodynamic analyses on novel hybrid compounds containing pyrazole and coumarin cores. J Mol Struct. 2018;1171:850–866.
  • Çapan İ, Gümüş M, Gökce H, et al. Synthesis, dielectric properties, molecular docking and ADME studies of pyrrole-3-ones. J Biomol Struct Dyn. 2021;1–17.
  • Lyne PD. Structure-based virtual screening: an overview. Drug Discov Today. 2002;7(20):1047–1055.
  • Dighe SN, Deora GS, De la Mora E, et al. Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem. 2016;59(16):7683–7689.
  • Schrödinger L. 2011. QikProp: rapid ADME predictions of drug candidates.
  • Lionta E, Spyrou G, K Vassilatis D, et al. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014;14(16):1923–1938.
  • Vidler LR, Filippakopoulos P, Fedorov O, et al. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J Med Chem. 2013;56(20):8073–8088.
  • Pitt WR, Calmiano MD, Kroeplien B, et al. 2013. Structure-based virtual screening for novel ligands. In: Protein-Ligand interactions. Totowa, NJ: Humana Press. p. 501–519.
  • Choudhary S, Malik YS, Tomar S. Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. Front Immunol. 2020;11:1664.
  • Adhikary R, Khandelwal R, Hussain T, et al. Structural insights into the molecular design of ROS1 inhibitor for the treatment of non-small cell lung cancer (NSCLC). CAD. 2021;17(3):387–401.
  • Aher A, Udhwani T, Khandelwal R, et al. In silico insights on IL-6: a potential target for multicentric castleman disease. Curr Comput Aided Drug Des. 2020;16(5):641–653.
  • Qureshi S, Khandelwal R, Madhavi M, et al. A multi-target drug designing for BTK, MMP9, proteasome and TAK1 for the clinical treatment of mantle cell lymphoma. CTMC. 2021;21(9):790–818.
  • Yadav M, Khandelwal R, Mudgal U, et al. Identification of potent VEGF inhibitors for the clinical treatment of glioblastoma, a virtual screening approach. Asian Pac J Cancer Prev. 2019;20(9):2681–2692.
  • Nayarisseri A, Khandelwal R, Tanwar P, et al. Artificial intelligence, big data and machine learning approaches in precision medicine & drug discovery. Curr Drug Targets. 2021.
  • Mendonça-Junior FJB, Scotti MT, Nayarisseri A, et al. Natural bioactive products with antioxidant properties useful in neurodegenerative diseases. Oxid Med Cell Longev. 2019;2019:7151780.
  • Celik I, Erol M, Puskullu MO, et al. Evaluation of activity of some 2, 5-disubstituted benzoxazole derivatives against acetylcholinesterase, butyrylcholinesterase and tyrosinase: ADME prediction, DFT and comparative molecular docking studies. Polycyclic Aromat Compd. 2020;1–12.
  • Pawar VS, Lokwani DK, Bhandari SV, et al. Design, docking study and ADME prediction of isatin derivatives as anti-HIV agents. Med Chem Res. 2011;20(3):370–380.
  • Dincel ED, Gürsoy E, Yilmaz-Ozden T, et al. Antioxidant activity of novel imidazo[2,1-b]thiazole derivatives: design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction. Bioorg Chem. 2020;103:104220.
  • Kumar S, Saini V, Maurya IK, et al. Design, synthesis, DFT, docking studies and ADME prediction of some new coumarinyl linked pyrazolylthiazoles: potential standalone or adjuvant antimicrobial agents. PloS One. 2018;13(4):e0196016.
  • Erol M, Celik I, Temiz-Arpaci O, et al. Synthesis, molecular docking and ADME prediction of some new benzimidazole carboxamidines derivatives as antimicrobial agents. Med Chem Res. 2020;29(11):2028–2038.
  • Kashid AM, Dube PN, Alkutkar PG, et al. Synthesis, biological screening and ADME prediction of benzylindole derivatives as novel anti-HIV-1, anti-fungal and anti-bacterial agents. Med Chem Res. 2013;22(10):4633–4640.
  • Kalin TN, Kilic D, Arslan F, et al. Synthesis, molecular modeling studies, ADME prediction of arachidonic acid carbamate derivatives, and evaluation of their acetylcholinesterase activity. Drug Dev Res. 2020;81(2):232–241.
  • Kumar A, Rathi E, Kini SG. E-pharmacophore modelling, virtual screening, molecular dynamics simulations and in-silico ADME analysis for identification of potential E6 inhibitors against cervical cancer. J Mol Struct. 2019;1189:299–306.
  • Bhatt JD, Chudasama CJ, Patel KD. Pyrazole clubbed triazolo [1, 5-a] pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study. Bioorg Med Chem. 2015;23(24):7711–7716.
  • Dofe VS, Sarkate AP, Lokwani DK, et al. Novel O‐alkylated chromones as antimicrobial agents: Ultrasound mediated synthesis, molecular docking and ADME prediction. J Heterocyclic Chem. 2017;54(5):2678–2685.
  • Malik R, Mehta P, Srivastava S, et al. Pharmacophore modeling, 3D-QSAR, and in silico ADME prediction of N-pyridyl and pyrimidine benzamides as potent antiepileptic agents. J Recept Signal Transduction. 2017;37(3):259–266.
  • da Silva Hage-Melim LI, Federico LB, de Oliveira NKS, et al. Virtual screening, ADME/tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19. Life Sci. 2020;256:117963.
  • Upadhyay S, Tripathi AC, Paliwal S, et al. 2-Pyrazoline derivatives in neuropharmacology: Synthesis, ADME prediction, molecular docking and in vivo biological evaluation. Excli J. 2017;16:628–649.
  • Pandey RK, Narula A, Naskar M, et al. Exploring dual inhibitory role of febrifugine analogues against plasmodium utilizing structure-based virtual screening and molecular dynamic simulation. J Biomol Struct Dyn. 2017;35(4):791–804.
  • Sadhasivam A, Vetrivel U. Identification of potential drugs targeting L,L‐diaminopimelate aminotransferase of Chlamydia trachomatis: an integrative pharmacoinformatics approach. J Cell Biochem. 2019;120(2):2271–2288.
  • Zakerali T, Shahbazi S. Rational druggability investigation toward selection of lead molecules: impact of the commonly used spices on inflammatory diseases. Assay Drug Dev Technol. 2018;16(7):397–407.
  • Suma KB, Kumari A, Shetty D, et al. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis. J Mol Graph Model. 2020;101:107718.
  • Sukumar N, Pask JE. Classical and enriched finite element formulations for bloch‐periodic boundary conditions. Int J Numer Meth Eng. 2009;77(8):1121–1138.
  • Rohini K, Ramanathan K, Shanthi V. Multi-dimensional screening strategy for drug repurposing with statistical framework—a new road to influenza drug discovery. Cell Biochem Biophys. 2019;77(4):319–333.
  • Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750–1759.
  • Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–234.
  • Lenselink EB, Beuming T, Sherman W, et al. Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor. J Chem Inf Model. 2014;54(6):1737–1746.
  • Verma P, Tiwari M, Tiwari V. In silico high-throughput virtual screening and molecular dynamics simulation study to identify inhibitor for AdeABC efflux pump of Acinetobacter baumannii. J Biomol Struct Dyn. 2018;36(5):1182–1194.
  • Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006;67(1):83–84.
  • Bhachoo J, Beuming T. Investigating protein–peptide interactions using the schrödinger computational suite. Modeling Peptide-Protein Interactions. 2017;1561:235–254.
  • Deb PK, Chandrasekaran B, Mailavaram R, et al. Molecular modeling approaches for the discovery of adenosine A2B receptor antagonists: current status and future perspectives. Drug Discov Today. 2019;24(9):1854–1864.
  • Vanajothi R, Hemamalini V, Jeyakanthan J, et al. Ligand-based pharmacophore mapping and virtual screening for identification of potential discoidin domain receptor 1 inhibitors. J Biomol Struct Dyn. 2020;38(9):2800–2808.
  • Politi A, Durdagi S, Moutevelis-Minakakis P, et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mol Graph Model. 2010;29(3):425–435.
  • Liu K, Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: a cross-docking study. J Chem Inf Model. 2017;57(10):2514–2522.
  • Munnaluri R, Sivan SK, Manga V. Molecular docking and MM/GBSA integrated protocol for designing small molecule inhibitors against HIV-1 gp41. Med Chem Res. 2015;24(2):829–841.
  • Lyne PD, Lamb ML, Saeh JC. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem. 2006;49(16):4805–4808.
  • Peddi SR, Sivan SK, Manga V. Molecular dynamics and MM/GBSA-integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors. J Biomol Struct Dyn. 2018;36(2):486–503.
  • Cheng F, Li W, Zhou Y, et al. admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J Chem Inf Model. 2012; 52(11):3099–3105.
  • Shen M, Zhou S, Li Y, et al. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Mol Biosyst. 2013;9(3):361–374.
  • Bathini R, Sivan SK, Fatima S, et al. Molecular docking, MM/GBSA and 3D-QSAR studies on EGFR inhibitors. J Chem Sci. 2016;128(7):1163–1173.
  • Pandey RK, Kumbhar BV, Sundar S, et al. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase. J Recept Signal Transduct Res. 2017;37(1):60–70.
  • Lagarias P, Barkan K, Tzortzini E, et al. Insights to the binding of a selective adenosine A3 receptor antagonist using molecular dynamic simulations, MM-PBSA and MM-GBSA free energy calculations, and mutagenesis. J Chem Inf Model. 2019;59(12):5183–5197.
  • Tang X, Wang Z, Lei T, et al. Importance of protein flexibility on molecular recognition: modeling binding mechanisms of aminopyrazine inhibitors to Nek2. Phys Chem Chem Phys. 2018;20(8):5591–5605.
  • Negron C, Pearlman DA, Del Angel G. Predicting mutations deleterious to function in beta-lactamase TEM1 using MM-GBSA. Plos One. 2019;14(3):e0214015.
  • Paissoni C, Spiliotopoulos D, Musco G, et al. GMXPBSA 2.1: a GROMACS tool to perform MM/PBSA and computational alanine scanning. Comput Phys Commun. 2015;186:105–107.
  • Salas-Burgos A, Iserovich P, Zuniga F, et al. Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J. 2004;87(5):2990–2999.
  • Shukla R, Chetri PB, Sonkar A, et al. Identification of novel natural inhibitors of opisthorchis felineus cytochrome P450 using structure-based screening and molecular dynamic simulation. J Biomol Struct Dyn. 2018;36(13):3541–3556.
  • Thirumal KD, Mendonca E, Priyadharshini CJ, et al. A computational model to predict the structural and functional consequences of missense mutations in O6-methylguanine DNA methyltransferase. Adv Protein Chem Struct Biol. 2019;115:351–369.
  • Shukla R, Shukla H, Kalita P, et al. Structural insights into natural compounds as inhibitors of Fasciola gigantica thioredoxin glutathione reductase. J Cell Biochem. 2018;119(4):3067–3080.
  • Kubarenko A, Frank M, Weber ANR. Structure–function relationships of toll-like receptor domains through homology modelling and molecular dynamics. Biochem Soc Trans. 2007;35(Pt 6):1515–1518.
  • Baul HS, Rajiniraja M. Mechanistic study of the inhibition of monoamine oxidase-B by quercetin as the potential therapeutic strategy for Parkinson’s disease: an in silico approach. JCM. 2018;18(4):1067–1073.
  • Di Prinzio CL, Pereyra RG. Molecular dynamics simulations of tilt grain boundaries in ice. Modelling Simul Mater Sci Eng. 2016;24(4):045015.
  • Shah M, Anwar MA, Yesudhas D, et al. A structural insight into the negative effects of opioids in analgesia by modulating the TLR4 signaling: an in silico approach. Sci Rep. 2016;6(1):1–15.
  • Tian J, Wang P, Gao S, et al. Enhanced thermostability of methyl parathion hydrolase from ochrobactrum sp. M231 by rational engineering of a glycine to proline mutation. Febs J. 2010;277(23):4901–4908.
  • Joshi T, Sharma P, Joshi T, et al. In silico screening of anti-inflammatory compounds from lichen by targeting cyclooxygenase-2. J Biomol Struct Dyn. 2020;38(12):3544–3562.
  • Torktaz I, Najafi A, Golmohamadi R, et al. Molecular dynamics simulation (MDS) analysis of Vibrio cholerae ToxT virulence factor complexed with docked potential inhibitors. Bioinformation. 2018;14(3):101–105.
  • Raftopoulou S, Nicolaides NC, Papageorgiou L, et al. 2020. Structural study of the DNA: Clock/Bmal1 complex provides insights for the role of cortisol, hGR, and HPA axis in stress management and sleep disorders. In: GeNeDis 2018. Cham: Springer. p. 59–71.
  • Muthuvel SK, Elumalai E, K G, et al. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor. J Recept Signal Transduct Res. 2018;38(5-6):475–483.
  • Gajendrarao P, Krishnamoorthy N, Sakkiah S, et al. Molecular modeling study on orphan human protein CYP4A22 for identification of potential ligand binding site. J Mol Graphics Modell. 2010;28(6):524–532.
  • Tanwar H, Kumar DT, Doss CGP, et al. Bioinformatics classification of mutations in patients with mucopolysaccharidosis IIIA. Metab Brain Dis. 2019;34(6):1577–1594.
  • Kumari R, Kumar R, Lynn A. Open source drug discovery consortium g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54(7):1951–1962,
  • Paissoni C, Spiliotopoulos D, Musco G, et al. GMXPBSA 2.0: a GROMACS tool to perform MM/PBSA and computational alanine scanning. Comput Phys Commun. 2014;185(11):2920–2929.
  • Wang E, Sun H, Wang J, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev. 2019;119(16):9478–9508.
  • Kumar A, Srivastava G, Negi AS, et al. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β. J Biomol Struct Dyn. 2019;37(2):275–290.
  • Botelho FD, Dos Santos MC, Gonçalves ADS, et al. Ligand-based virtual screening, molecular docking, molecular dynamics, and MM-PBSA calculations towards the identification of potential novel ricin inhibitors. Toxins. 2020;12(12):746.
  • Elkarhat Z, Charoute H, Elkhattabi L, et al. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. J Biomol Struct Dyn. 2020;40:361–374.
  • Martins LC, Torres PHM, de Oliveira RB, et al. Investigation of the binding mode of a novel cruzain inhibitor by docking, molecular dynamics, ab initio and MM/PBSA calculations. J Comput Aided Mol Des. 2018;32(5):591–605.
  • Kumari R, Lynn A. Application of MM/PBSA in the prediction of relative binding free energy: Re-scoring of docking hit-list. J Nat Sci, Biol Med. 2011;2(3):92–92.
  • Shenai PM, Xu Z, Zhao Y. Applications of principal component analysis (PCA) in materials science. Principal Component Analysis–Engineering Application. 2012. p. 25–40.
  • Chen J, Wang J, Zhu W. Molecular mechanism and energy basis of conformational diversity of antibody SPE7 revealed by molecular dynamics simulation and principal component analysis. Sci Rep. 2016;6(1):36900–36912.
  • Sittel F, Filk T, Stock G. Principal component analysis on a torus: theory and application to protein dynamics. J Chem Phys. 2017;147(24):244101.
  • Riccardi L, Nguyen PH, Stock G. Free-energy landscape of RNA hairpins constructed via dihedral angle principal component analysis. J Phys Chem B. 2009;113(52):16660–16668.
  • Buslaev P, Mustafin K, Gushchin I. Principal component analysis highlights the influence of temperature, curvature and cholesterol on conformational dynamics of lipids. Biochim Biophys Acta Biomembr. 2020;1862(7):183253.
  • Nguyen PH. Complexity of free energy landscapes of peptides revealed by nonlinear principal component analysis. Proteins Struct Funct Bioinf. 2006;65(4):898–913.
  • Yamamoto N. Hot spot of structural ambivalence in prion protein revealed by secondary structure principal component analysis. J Phys Chem B. 2014;118(33):9826–9833.
  • Michielssens S, van Erp TS, Kutzner C, et al. Molecular dynamics in principal component space. J Phys Chem B. 2012;116(29):8350–8354.
  • Grasso G, Deriu MA, Tuszynski JA, et al. Conformational fluctuations of the AXH monomer of ataxin‐1. Proteins. 2016;84(1):52–59.
  • Verma S, Singh A, Kumari A, et al. Natural polyphenolic inhibitors against the antiapoptotic BCL-2. J Recept Signal Transduct Res. 2017;37(4):391–400.
  • Mouritsen OG, Khandelia H. Molecular mechanism of the allosteric enhancement of the umami taste sensation. Febs J. 2012;279(17):3112–3120.
  • Swain SS, Paidesetty SK, Dehury B, et al. Molecular docking and simulation study for synthesis of alternative dapsone derivative as a newer antileprosy drug in multidrug therapy. J Cell Biochem. 2018;119(12):9838–9852.
  • Villa A, Stock G. What NMR relaxation can tell us about the internal motion of an RNA hairpin: a molecular dynamics simulation study. J Chem Theory Comput. 2006;2(5):1228–1236.
  • Ng HW, Laughton CA, Doughty SW. Molecular dynamics simulations of the adenosine A2a receptor: structural stability, sampling, and convergence. J Chem Inf Model. 2013;53(5):1168–1178.
  • Bruker S. SAINT and SADABS. Madison, Wisconsin: Bruker AXS Inc.; 2005.
  • Sheldrick GM. A short history of SHELX. Acta Crystallogr A. 2008; 64(Pt 1):112–122.
  • Macrae CF, Bruno IJ, Chisholm JA, et al. Mercury CSD 2.0 - new features for the visualization and investigation of crystal structures. J Appl Crystallogr. 2008;41(2):466–470.
  • Spek AL. Structure validation in chemical crystallography. Acta Crystallogr D Biol Crystallogr. 2009;65(Pt 2):148–155.
  • Brandenburg K, Putz H. DIAMOND, crystal impact GbR. Germany: Bonn; 2005.
  • McKinnon JJ, Jayatilaka D, Spackman MA. Towards quantitative analysis of intermolecular interactions with hirshfeld surfaces. Chem Commun. 2007;37:3814–3816.
  • McKinnon JJ, Mitchell AS, Spackman MA. Hirshfeld surfaces: a new tool for visualising and exploring molecular crystals. Chem Eur J. 1998;4(11):2136–2141.
  • McKinnon JJ, Spackman MA, Mitchell AS. Novel tools for visualizing and exploring intermolecular interactions in molecular crystals. Acta Crystallogr B. 2004;60(Pt 6):627–668.
  • Turner MJ, McKinnon JJ, Wolff SK, et al. Crystal explorer. Perth, Australia: University of Western Australia; 2017.
  • Spackman MA, McKinnon JJ. Fingerprinting intermolecular interactions in molecular crystals. CrystEngComm. 2002;4(66):378–392.
  • Venkatesan P, Thamotharan S, Ilangovan A, et al. Crystal structure, Hirshfeld surfaces and DFT computation of NLO active (2E)-2-(ethoxycarbonyl)-3-[(1-methoxy-1-oxo-3-phenylpropan-2-yl)amino] prop-2-enoic acid. Spectrochim Acta A Mol Biomol Spectrosc. 2016; 153:625–636.
  • Kremer W, Weyand M, Winklmeier A, et al. 1.2 Å X-ray structure of the renal potassium channel K v 1.3 T1 domain. Protein J. 2013;32(7):533–542.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.